Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

NCT06465433 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT06465433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Recruiting
Start date
November 8, 2022
Completion date
August 29, 2027
Enrollment
25 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies